Want to see ELTX full AI Analyst Report?
Top Page
Elicio Therapeutics
(NASDAQ:ELTX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$3.00
▲(0.00% Upside)
Action:Reiterated
Date:08/17/26
The score is primarily held down by weak financial performance (no revenue and sustained ~$37M+ annualized cash burn) and a bearish technical trend with the stock trading well below key moving averages. Corporate events provide partial support via new financing and some encouraging clinical signals, but the missed Phase 2 primary endpoint remains a significant offset. Valuation contributes little because the negative P/E reflects ongoing losses and there is no dividend yield.
Positive Factors
Potentially Differentiated Immunotherapy Platform
Complete responses after ELI-002 7P followed by nivolumab, alongside persistent KRAS-specific T-cell responses, suggest the AMP platform may prime tumors for checkpoint therapy. If confirmed prospectively, this could differentiate Elicio in a high-unmet-need cancer setting.
Negative Factors
No Commercial Revenue
Elicio has no approved commercial product and therefore lacks recurring product revenue. Continued losses without operating revenue leave the company dependent on clinical progress, partnerships, or capital markets to fund its business.
Read all positive and negative factors
Positive Factors
Negative Factors
Potentially Differentiated Immunotherapy Platform
Complete responses after ELI-002 7P followed by nivolumab, alongside persistent KRAS-specific T-cell responses, suggest the AMP platform may prime tumors for checkpoint therapy. If confirmed prospectively, this could differentiate Elicio in a high-unmet-need cancer setting.
Read all positive factors
Elicio Therapeutics (ELTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$81.74M
Dividend YieldN/A
Average Volume (3M)3.31M
Price to Earnings (P/E)―
Beta (1Y)0.72
Revenue GrowthN/A
EPS Growth49.43%
CountryUS
Employees33
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.13
Shares Outstanding26,281,881
10 Day Avg. Volume474,004
30 Day Avg. Volume3,311,596
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)74.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.30
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.67Price Target Upside588.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.03
Revenue Forecast (FY)N/A
Elicio Therapeutics Business Overview & Revenue Model
Company Description
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an A...
How the Company Makes Money
As a clinical-stage biotechnology company, Elicio Therapeutics historically has not generated revenue from product sales because it does not have an approved therapy on the market. Its ability to generate income is therefore primarily tied to exte...
Elicio Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.31M |
| Gross Profit | -289.00K | -1.13M | -1.18M | -1.17M | -1.06M | 27.08M |
| EBITDA | -40.51M | -37.31M | -50.27M | -32.97M | -23.55M | -51.92M |
| Net Income | -37.84M | -39.57M | -51.90M | -35.20M | -28.21M | -26.40M |
Balance Sheet | ||||||
| Total Assets | 31.33M | 25.86M | 28.18M | 27.15M | 22.66M | 96.51M |
| Cash, Cash Equivalents and Short-Term Investments | 23.48M | 18.56M | 17.62M | 12.89M | 7.80M | 88.76M |
| Total Debt | 14.15M | 14.51M | 26.04M | 6.92M | 7.48M | 4.66M |
| Total Liabilities | 23.39M | 24.23M | 39.49M | 15.77M | 13.75M | 15.01M |
| Stockholders Equity | 7.94M | 1.64M | -11.31M | 11.37M | 8.91M | 81.51M |
Cash Flow | ||||||
| Free Cash Flow | -37.71M | -36.97M | -37.16M | -32.76M | -22.83M | -24.46M |
| Operating Cash Flow | -37.69M | -36.95M | -37.07M | -32.69M | -22.18M | -23.94M |
| Investing Cash Flow | -16.00K | -16.00K | -84.00K | -32.00K | -654.00K | -525.36K |
| Financing Cash Flow | 38.97M | 36.70M | 42.32M | 38.61M | 21.20M | 19.39M |
Elicio Therapeutics Technical Analysis
Neutral
3.00
Price Trends
4.23
Negative
7.65
Negative
8.39
Negative
Market Momentum
-0.30
Negative
42.48
Neutral
29.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELTX, the sentiment is Neutral. The current price of 3 is below the 20-day moving average (MA) of 3.05, below the 50-day MA of 4.23, and below the 200-day MA of 8.39, indicating a neutral trend. The MACD of -0.30 indicates Negative momentum. The RSI at 42.48 is Neutral, neither overbought nor oversold. The STOCH value of 29.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ELTX.
Elicio Therapeutics Risk Analysis
Elicio Therapeutics disclosed 93 risk factors in its most recent earnings report. Elicio Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Elicio Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $225.04M | 6.50 | 42.57% | ― | 234.18% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $133.21M | -1.57 | -288.36% | ― | ― | 21.42% | |
45 Neutral | $43.15M | -1.93 | -60.32% | ― | ― | 71.26% | |
44 Neutral | $81.74M | -1.47 | -1266.43% | ― | ― | 49.43% |
* Healthcare Sector Average
ELTX
Elicio Therapeutics
3.13
-8.12
-72.18%
CGEN
Compugen
2.44
1.00
69.44%
MCRB
Seres Therapeutics
4.68
-13.26
-73.91%
MIST
Milestone Pharmaceuticals
1.08
-0.56
-34.15%
ACTU
Actuate Therapeutics, Inc.
1.06
-6.62
-86.20%
Elicio Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Elicio Therapeutics announces $15 million direct offering
Positive
Jul 2, 2026
On July 1, 2026, Elicio Therapeutics entered a securities purchase agreement with institutional investors for a registered direct offering of 4,380,313 common shares at $3.43 each. The deal, led by two new fundamental investors with support from a...
Business Operations and StrategyProduct-Related Announcements
Elicio Highlights ELI-002 7P Progress in Pancreatic Cancer
Positive
Jun 24, 2026
On June 24, 2026, Elicio Therapeutics hosted a virtual key opinion leader event to outline the development path for its ELI-002 7P candidate in metastatic mutant KRAS pancreatic ductal adenocarcinoma, featuring clinical and academic experts from U...
Business Operations and Strategy
Elicio Highlights Promising Synergy With Checkpoint Inhibitor Therapy
Positive
Jun 17, 2026
On June 17, 2026, Elicio Therapeutics reported preliminary observations from its Phase 2 AMPLIFY-7P trial showing three metastatic mKRAS pancreatic cancer patients, who had progressed after ELI-002 7P and chemotherapy, later achieved confirmed com...
Business Operations and Strategy
Elicio Unveils Phase 2 ELI-002 Results and Phase 3 Plan
Negative
Jun 15, 2026
On June 15, 2026, Elicio Therapeutics reported topline results from its randomized Phase 2 AMPLIFY-7P trial of ELI-002 7P in adjuvant mutant KRAS-driven pancreatic ductal adenocarcinoma following standard locoregional therapy. The study did not me...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.